This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas (IELSG33)
In this study, the investigators propose that the addition of rituximab will lower the risk of systemic and local relapses in patients with localized PBL. Patients will be treated with 6 cycles of RCHOP-14 or RCHOP-21. The administration of radiotherapy following chemotherapy is strongly recommended, based on the findings of the retrospective IELSG study, but will be at the discretion of the treating center.
Diffuse Large B Cell Lymphoma of the Breast.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||A Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas Treated With R-CHOP With or Without Radiotherapy|
- local and CNS relapse rate
- progression free survival [ Time Frame: 12-month ]
- overall survival [ Time Frame: 5-year ]
- overall, complete and partial response rates following RCHOP [ Time Frame: at the end of chemotherapy ]
|Study Start Date:||October 2011|
No Contacts or Locations Provided